Peroral administration of medroxyprogesterone acetate (MPA) in advanced cancer of the breast. A preliminary report
Møller, K.A.; Andersen, A.P.
Acta obstetricia et gynecologica Scandinavica. Supplement 101: 47-48
1981
ISSN/ISBN: 0300-8835 PMID: 7030001 Document Number: 172164
Document emailed within 1 workday
Related Documents
Guarnieri, A.; Tucci, E.; D'Aniello, C.; Carli, A.; Mariani, L.; De Stefano, A.; Nardi, P. 1984: Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 3(5): 320-323Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362
Lorenz, I.; Mechl, Z. 1985: Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer Neoplasma 32(1): 119-124
Mitsuyama, S.; Kuroda, Y.; Ohsato, K.; Nakamura, Y.; Murakami, F.; Nishikata, F.; Ikeda, S.; Egami, T.; Mori, A.; Ohe, H. 1996: Administration method and recurrence-preventing effect of medroxyprogesterone acetate (MPA) as a postoperative adjuvant endocrine therapy for stage III breast cancer. Kitakyushu Collaborative Study Group for Breast Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(9): 1153-1160
Pannuti, F.; Di Marco, A.R.; Martoni, A.; Fruet, F.; Strocchi, E.; Burroni, P.; Marraro, D. 1982: Medroxyprogesterone acetate (MAP) in high doses in the treatment of breast cancer in advanced stages Minerva Ginecologica 34(11): 977-979
Kihara, M.; Kontani, K.; Yamauchi, A.; Yokomise, H. 2005: Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 32(5): 683-686
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Cohen, C.J.; Deppe, G.; Bruckner, H.W. 1977: Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study Obstetrics and Gynecology 50(4): 415-417
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
Sonoo, H.; Senoo, T.; Nishiki, M.; Morimoto, T.; Takashima, S. 1996: Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA Gan to Kagaku Ryoho. Cancer and ChemoTherapy 23(4): 447-454
Kaunitz, A.M. 1996: Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer Journal of Reproductive Medicine 41(5 Suppl): 419-427
Pannuti, F.; Camaggi, C.M.; Strocchi, E.; Giovannini, M.; Di Marco, A.R.; Costanti, B. 1982: Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients Cancer Treatment Reports 66(12): 2043-2049
Sica, G.; Lama, G.; Iacopino, F.; Angelucći, C.; Della Cuna, G.R.; Marchetti, P. 1991: Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells Anticancer Research 11(6): 2099-2102
Toi, M.; Taniguchi, T.; Hayashi, K.; Tominaga, T. 1995: The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(6): 799-804
Klaassen, D.J.; Rapp, E.F.; Hirte, W.E. 1976: Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women Cancer Treatment Reports 60(3): 251-253
Izumi, M.; Iino, Y.; Yokoe, T.; Inoue, T.; Yamada, T.; Kobayashi, I.; Andoh, T.; Yokota, T.; Iijima, T.; Morishita, Y. 1994: Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(2): 265-268
Takatsuka, Y.; Katoh, T.; Tsumura, I.; Kobayakawa, K.; Kawahara, T. 1992: Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 19(1): 107-110
Iba, T.; Kidokoro, A.; Fukunaga, M.; Sugiyama, K.; Aihara, N.; Suda, M. 2001: The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients Gan to Kagaku Ryoho. Cancer and ChemoTherapy 28(7): 973-977
Sadoff, L.; Lusk, W. 1974: The effect of large doses of medroxyprogesterone acetate (MPA) on urinary estrogen levels and serum levels of cortisol T4 LH and testosterone in patients with advanced cancer Obstetrics and Gynecology 43(2): 262-267
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405